ScreenerHero

CLRBCellectar Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cellectar.com
2.590USD-1.15%Mkt Cap: 24.48M $P/E: —

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid d…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap24.48M $
Enterprise Value-7.98M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-21.79M $
Revenue/Share—
Last Price2.590 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS15117F8077
Valuation
P/E (Trailing)—
P/E (Forward)-1.35
PEG—
EV/EBITDA0.34
EV/Revenue—
P/S—
P/B0.72
EPS (TTM)-2.13
EPS (Forward)-1.92
52W Range
2.2009% of range6.520
52W High6.520 USD
52W Low2.200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-255.25%
ROA-145.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.12M $
CapEx (TTM)5.88K $
FCF Margin—
FCF Yield-50.13%
Net Debt-32.46M $
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.05
Current Ratio6.66
Quick Ratio6.49
Book Value/Sh3.620 USD
Cash/Share3.596 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 17, 2018
Splits
Last Split1:30
Split DateJun 24, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.50 USD
Upside (mean)+344.0%
Target Range10.00 USD – 15.00 USD
$10.00+344.0% to mean$15.00
# Analysts4
Ownership
Shares Out.9.45M
Float9.25M
Insiders1.75%
Institutions34.71%
Short Interest
Short Ratio1.8d
Short % Float2.20%
Short % Out.2.19%
Shares Short174.83K
Short (prev mo.)194.34K
Technical
SMA 502.563 (+1.1%)
SMA 2002.980 (-13.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)67.42K
Avg Vol (10d)34.49K
Technical Indicators
RSI (14)50.8
MACD-0.0018
MACD Signal-0.0114
MACD Hist.+0.0097
BB Upper2.684 USD
BB Middle2.545 USD
BB Lower2.406 USD
BB Width10.94%
ATR (14)0.1428 USD
Vol Ratio (20d)0.62x